Skip to content

The Effect of Continuous Intravenous Magnesium Sulfate Infusion on the Incidence of Atrial Fibrillation After Cardiac Surgery: A Prospective Randomized Controlled Clinical Trial

The Effect of Continuous Intravenous Magnesium Sulfate Infusion on the Incidence of Atrial Fibrillation After Cardiac Surgery: A Prospective Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129626
Enrollment
Unknown
Registered
2026-08-07
Start date
2026-08-10
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Atrial Fibrillation (POAF)

Interventions

Placebo group:Continuous intravenous infusion of 0.9% normal saline
Magnesium Sulfate group:Continuous Intravenous Magnesium Sulfate Infusion

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18–85 years scheduled for elective isolated coronary artery bypass grafting (CABG) under cardiopulmonary bypass; 2. Preoperative heart rate >=50 beats per minute (bpm), with sinus rhythm or correctable cardiac arrhythmias; 3. Provision of signed informed consent, with the ability to understand the study procedures and a willingness to participate voluntarily. 4. Preoperative serum magnesium levels within the normal range (0.75–1.05 mmol/L). 5. No contraindications to the planned surgical procedures or standard perioperative management.

Exclusion criteria

Exclusion criteria: 1. Patients scheduled for emergency or urgent cardiac surgery; 2. Combined cardiac procedures (e.g., CABG combined with valve surgery, double or multiple valve surgery, or great vessel surgery); 3. Redo cardiac surgery (history of prior cardiac surgery via thoracotomy); 4. History of atrial fibrillation or other cardiac arrhythmias; 5. Preoperative hemodynamic instability (e.g., cardiogenic shock, dependence on continuous intravenous vasopressors to maintain blood pressure, or preoperative use of mechanical circulatory support such as IABP or ECMO); 6. Severe baseline hypotension (e.g., systolic blood pressure = 40 kg/m².

Design outcomes

Primary

MeasureTime frame
Incidence of new-onset postoperative atrial fibrillation (POAF) within the first 5 postoperative days;

Secondary

MeasureTime frame
Duration of postoperative atrial fibrillation;ICU and hospital length of stay;Serious adverse events (SAEs) such as postoperative hypotension and heart rate abnormalities;

Countries

China

Contacts

Public ContactChanghong Miao

Zhongshan Hospital, Fudan University

miao.changhong@zs-hospital.sh.cn+86 21 64041990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026